4-Hydroxy-3-iodobenzoic acid, 95.0%, 10g

6-Amino-4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-7-ethoxyquinoline-3-carbonitrile, 98%, 100g

3-Bromo-2-fluoro-5-methyl pyridine, 98.0%, 100g

6-Iodobenzo[d]thiazol-2-amine, 95.0%, 100mg

(S)-2-((tert-Butoxycarbonyl)amino)-3-(o-tolyl)propanoic acid, 95.0%, 1g

(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(methylsulfonyl)butanoic acid, 96%, 250mg

1-(Methoxymethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 95%, 250mg

Seringue microlitre GASTIGHT® série 1700 Point type 2, 50 µl, 1705 RN, 1 pièce

2-Chloro-N-thiazol-2-yl-acetamide, 95.0%, 2.5g

2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinic acid, 500mg

ethyl 5-(3-iodophenyl)-5-oxovalerate, 97.0%, 1g

1-Bromo-3-(trifluoromethoxy)benzene, 97.0%, 500g

((3aR,4R,6R,6aR)-6-(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,2,3a-trimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol, 98%, 250mg